Avipaxin Is First Entrant in Medical Arsenal for Neuro-Endocrine-Immune Connection(C) Product and Testing Protocols
OSCEOLA, Wis., Aug. 4 /PRNewswire/ — NeuroScience, Inc. has launched a new product — Avipaxin — aimed at decreasing elevated levels of pro-inflammatory cytokines. Avipaxin supports acetylcholine levels by providing substrates for its production and by inhibiting its metabolizing enzyme, acetylcholinesterase. Initial studies at NeuroScience, Inc. revealed a significant decrease in pro-inflammatory cytokines and chemokines after Avipaxin use. These studies also revealed a decrease in the neurotransmitter norepinephrine and an increase in the neurotransmitter serotonin.
Historically, neurotransmitters, cytokines, and hormones were considered signal messengers of the Nervous, Endocrine, and Immune systems, respectively. However, recent evidence shows that those systems are actually part of a single and integrated Neuro-Endocrine-Immune (NEI) Connection(C).
Elevated pro-inflammatory cytokine levels lead to imbalances in neurotransmitter concentrations and raised hormone (cortisol) levels. Neurotransmitters are responsible for people’s mood, concentration, sleep, and other mental and emotional functions. Cytokine-induced neurotransmitter imbalances are regularly noticed when people are sad, lethargic, and are unable to focus during an acute viral or bacterial infection. Serotonin, which was increased in the Avipaxin studies, is a particularly important neurotransmitter involved with mood and sleep. Research shows that persistent cytokine elevations lead to numerous physical and emotional symptoms that are difficult to manage.
Avipaxin modulates elevated cytokine levels by supporting acetylcholine-mediated signaling. The cholinergic anti-inflammatory pathway uses the neurotransmitter acetylcholine to down-regulate elevated pro-inflammatory cytokines. Decreasing pro-inflammatory cytokines leads to an indirect normalization of neurotransmitter levels, leading to a positive effect on mood, concentration, sleep, and other emotional and mental processes. Avipaxin should be considered for patients with suspected acute or persistent immune system activation.
Additional information regarding Avipaxin can be found at www.neurorelief.com/avipaxin.
About NeuroScience, Inc.:
NeuroScience, Inc, established in 1999, is devoted to medical solutions that improve health by providing novel laboratory assessments and products in the emerging field of NeuroEndocrine Immunology (NEI). The company is research and education-focused and has a database that includes results from over 300,000 patients.
SOURCE NeuroScience, Inc.